The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer
Open accessAbstract
A phase III randomised study, comparing treatment with fluorouracil, epidoxorubicin and methotrexate (FEMTX) with the best supportive care, was conducted in patients with unresectable or metastatic gastric cancer. During the period from July 1986 to June 1992, 41 patients were randomised to receive FEMTX or best supportive care. MTX was given in a dose of 1500 mg m-2 intravenously (i.v.) followed after 1 h by 5-FU 1500 mg m-2 i.v. on day 1; leucovorin rescue was started after 24 h (30 mg orally every 6 h for 48 h) and epidoxorubicin 60 mg m-2 i.v. was administered on day 15. In addition both groups received tablets containing vitamins A and E. Response rates for FEMTX were as follows: complete response (CR), 19% (4/21); partial response (PR), 10% (2/21); no change (NC), 33% (7/21); and progressive disease (PD), 24% (5/21). Response rates in the control group were: NC, 20% (4/20); and PD, 80% (16/20). Increased pain was observed in one patient in the treated group and in 11 patients in the control group within the first 2 months. WHO grade III/IV toxicity in the chemotherapy group was as follows: nausea/vomiting 40%, diarrhoea 10%, stomatitis 15%, leucopenia 50% and thrombocytopenia 10%. One possible treatment-related death was due to sepsis. The median time to progression in the FEMTX group was 5.4 months [95% confidence interval (CI) 3.1-11.7 months], but only 1.7 months in the control group (95% CI 1.2-2.7 months) (P = 0.0013). Similarly, the FEMTX group displayed significantly (P = 0.0006) prolonged survival compared with the control group, i.e. median survival 12.3 months (95% CI 7.1-15.6 months) vs 3.1 months (95% CI 1.6-4.6 months). In conclusion, FEMTX combined with vitamin A and E is a fairly well-tolerated treatment, giving a response rate of 29% in patients with advanced gastric cancer, and also prolonging patients' survival. It can be used as a reference treatment in testing new investigational combinations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Assessment of response to therapy in advanced breast cancer
Hayward, J. L., Carbone, P. P., Heusen, J. C., Kumaoka, S., Segaloff, A., & Rubens, R. D. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.42 · Cited by 705
Cullinan, S. A. (1985) · JAMA · doi:10.1001/jama.253.14.2061 · Cited by 391
Wils, J., Klein, H. O., Wagener, D. J. T., Bleiberg, H., Reis, H. E., Korsten, F. W., Conroy, T., Fickers, M. M. F., Leyvraz, S., & Buyse, M. E. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.5.827 · Cited by 388
Chemotherapy of carcinoma of the stomach
Findlay, M. P. N., & Cunningham, D. (1993) · Cancer Treatment Reviews · doi:10.1016/0305-7372(93)90025-m · Cited by 54
Pyrhönen, S. O., & Kouri, M. (1992) · European Journal of Cancer · doi:10.1016/0959-8049(92)90014-s · Cited by 11
Self-citationKohnoe, S., Yoshida, M., Takahashi, I., Emi, Y., Maehara, Y., & Sugimachi, K. (1992) · PubMed · Cited by 5
Cited by
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073149 · Cited by 2,285
Japanese gastric cancer treatment guidelines 2010 (ver. 3)
Japanese Gastric Cancer Association (2011) · Gastric Cancer · doi:10.1007/s10120-011-0042-4 · Cited by 2,168
Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8429 · Cited by 1,926
Koizumi, W., Narahara, H., Hara, T., Takagane, A., Akiya, T., Takagi, M., Miyashita, K., Nishizaki, T., Kobayashi, O., Takiyama, W., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70035-4 · Cited by 1,847
Japanese gastric cancer treatment guidelines 2018 (5th edition)
Japanese Gastric Cancer Association (2021) · Gastric Cancer · doi:10.1007/s10120-020-01042-y · Cited by 1,749
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Chemotherapy for advanced gastric cancer
Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B.-C., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,299
Wagner, A. D., Grothe, W., Haerting, J., Kleber, G., Grothey, A., & Fleig, W. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0245 · Cited by 1,171
Glimelius, B., Ekström, K., Hoffman, K., Graf, W., Sjödén, P.-O., Haglund, U., Svensson, C., Enander, L.-K., Linné, T., Sellsröm, H., et al. (1997) · Annals of Oncology · doi:10.1023/a:1008243606668 · Cited by 849
Guidelines for the management of oesophageal and gastric cancer
Allum, W. H., Blazeby, J. M., Griffin, S. M., Cunningham, D., Jankowski, J. A., Wong, R., & On behalf of the Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, T. B. S. O. G. A. T. B. A. O. S. O. (2011) · Gut · doi:10.1136/gut.2010.228254 · Cited by 793
Gastric Adenocarcinoma: Review and Considerations for Future Directions
Dicken, B. J., Bigam, D. L., Cass, C., Mackey, J. R., Joy, A. A., & Hamilton, S. M. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000149300.28588.23 · Cited by 691
Interventions for treating oral mucositis for patients with cancer receiving treatment
Clarkson, J. E., Worthington, H. V., Furness, S., McCabe, M., Khalid, T., & Meyer, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001973.pub4 · Cited by 674
Thuss-Patience, P. C., Kretzschmar, A., Bichev, D., Deist, T., Hinke, A., Breithaupt, K., Dogan, Y., Gebauer, B., Schumacher, G., & Reichardt, P. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.002 · Cited by 612
Boku, N., Yamamoto, S., Fukuda, H., Shirao, K., Doi, T., Sawaki, A., Koizumi, W., Saito, H., Yamaguchi, K., Takiuchi, H., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70259-1 · Cited by 586
Gastric cancer treatment guidelines in Japan
Nakajima, T. (2002) · Gastric Cancer · doi:10.1007/s101200200000 · Cited by 569
Hironaka, S., Ueda, S., Yasui, H., Nishina, T., Tsuda, M., Tsumura, T., Sugimoto, N., Shimodaira, H., Tokunaga, S., Moriwaki, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5805 · Cited by 541
Chau, I., Norman, A. R., Cunningham, D., Waters, J. S., Oates, J., & Ross, P. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.154 · Cited by 524
Ross, P., Nicolson, M., Cunningham, D., Valle, J., Seymour, M., Harper, P., Price, T., Anderson, H., Iveson, T., Hickish, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.105 · Cited by 475
Should Supplemental Antioxidant Administration Be Avoided During Chemotherapy and Radiation Therapy?
Lawenda, B. D., Kelly, K. M., Ladas, E. J., Sagar, S. M., Vickers, A., & Blumberg, J. B. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn148 · Cited by 472
Chemotherapy for advanced gastric cancer
Wagner, A. D., Unverzagt, S., Grothe, W., Kleber, G., Grothey, A., Haerting, J., & Fleig, W. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub3 · Cited by 472
Ohtsu, A., Shimada, Y., Shirao, K., Boku, N., Hyodo, I., Saito, H., Yamamichi, N., Miyata, Y., Ikeda, N., Yamamoto, S., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.130 · Cited by 427
Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach
Guideline Committee of the Korean Gastric Cancer Association (KGCA), D. W. G. &. R. P. (2019) · Journal of Gastric Cancer · doi:10.5230/jgc.2019.19.e8 · Cited by 392
Catalano, V., Labianca, R., Beretta, G. D., Gatta, G., de Braud, F., & Van Cutsem, E. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.01.004 · Cited by 365
Singh, K., Bhori, M., Kasu, Y. A., Bhat, G., & Marar, T. (2018) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2017.12.013 · Cited by 288
Xu, J., Liu, D., Niu, H., Zhu, G., Xu, Y., Ye, D., Li, J., & Zhang, Q. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0487-8 · Cited by 283
Crumley, A. B. C., McMillan, D. C., McKernan, M., McDonald, A. C., & Stuart, R. C. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602998 · Cited by 281
Waters, J. S., Norman, A., Cunningham, D., Scarffe, J. H., Webb, A., Harper, P., Joffe, J. K., Mackean, M., Mansi, J., Leahy, M., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690350 · Cited by 275
Bouché, O., Raoul, J. L., Bonnetain, F., Giovannini, M., Etienne, P. L., Lledo, G., Arsène, D., Paitel, J. F., Guérin-Meyer, V., Mitry, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.140 · Cited by 274
Guidelines for the management of oesophageal and gastric cancer
Allum, W. H., Griffin, S. M., Watson, A., & Colin-Jones, D. (2002) · Gut · doi:10.1136/gut.50.suppl_5.v1 · Cited by 273
Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial
Bramhall, S. R., Hallissey, M. T., Whiting, J., Scholefield, J., Tierney, G., Stuart, R. C., Hawkins, R. E., McCulloch, P., Maughan, T., Brown, P. D., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600310 · Cited by 265
Ham, I.-H., Oh, H. J., Jin, H., Bae, C. A., Jeon, S.-M., Choi, K. S., Son, S.-Y., Han, S.-U., Brekken, R. A., Lee, D., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0972-8 · Cited by 264
Interventions for preventing oral mucositis for patients with cancer receiving treatment
Worthington, H. V., Clarkson, J. E., Bryan, G., Furness, S., Glenny, A.-M., Littlewood, A., McCabe, M. G., Meyer, S., Khalid, T., & Riley, P. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000978.pub5 · Cited by 262
Metadata
- Authors
- Pyrhönen, S., Kuitunen, T., Nyandoto, P., & Kouri, M.
- Venue
- British Journal of Cancer
- Published
- 1995-03-01
- Volume
- 71
- Issue
- 3
- Pages
- 587-591
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1992408996
- Cited by
- 789
- References
- 8
- FWCI
- 5.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.